Holen Sie sich die Stockscreener-App
69.12
1.65%
-1.16
Vorhandelsmarkt:
68.75
-0.37
-0.54%
Schlusskurs vom Vortag:
$70.28
Offen:
$70.56
24-Stunden-Volumen:
1.83M
Relative Volume:
0.72
Marktkapitalisierung:
$13.54B
Einnahmen:
$502.08M
Nettoeinkommen (Verlust:
$-732.94M
KGV:
-18.27
EPS:
-3.7842
Netto-Cashflow:
$-455.50M
1W Leistung:
+4.52%
1M Leistung:
-7.15%
6M Leistung:
+1.48%
1J Leistung:
+109.65%
1-Tages-Spanne:
$68.42
$71.74
1-Wochen-Bereich:
$63.63
$71.74
52-Wochen-Spanne:
$31.77
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
69.12 | 13.77B | 502.08M | -732.94M | -455.50M | -3.7842 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma, Inc. (BBIO) Growth Potential: Analyst Ratings Signal 47% Upside - DirectorsTalk Interviews
Technical Reactions to BBIO Trends in Macro Strategies - Stock Traders Daily
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
BBIO (NASDAQ: BBIO) trust sells repeated 20,000-share blocks under 10b5-1 - Stock Titan
BBIO Stock Price Prediction 2025-2026 | BridgeBio Pharma Inc Forecast - 24/7 Wall St.
BridgeBio’s SWOT analysis: rare disease stock eyes profitability By Investing.com - Investing.com Canada
BridgeBio’s SWOT analysis: rare disease stock eyes profitability - Investing.com
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM) - The Globe and Mail
BBIO Initiates Coverage by Citigroup -- Rating Set to Neutral - GuruFocus
J.P. Morgan Initiates BridgeBio Pharma(BBIO.US) With Hold Rating, Announces Target Price $82 - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $671,456, According to a Recent SEC Filing - Moomoo
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
BridgeBio Pharma (BBIO) CEO reports RSU vesting and tax withholding share disposition - Stock Titan
BridgeBio (BBIO) CAO has 4,714 shares withheld at $66.13 for RSU taxes - Stock Titan
BridgeBio Pharma (BBIO) director exercises options and sells 10,000 shares - Stock Titan
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk - Yahoo Finance
BridgeBio falls despite new Attruby data - MSN
Citigroup initiates coverage of BridgeBio Pharma (BBIO) with neutral recommendation - MSN
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a 55% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Janus Henderson (BBIO) discloses 13,179,013 shares, 6.8% ownership - Stock Titan
How Encaleret’s NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investors’ Outlook - Yahoo Finance
BridgeBio (BBIO) Q1 2026 Earnings Transcript - AOL.com
BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseases - AD HOC NEWS
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
BridgeBio outlines $500M share repurchase as it targets P&L breakeven in 2027 - MSN
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $101 - Moomoo
BridgeBio Files FDA NDA for Encaleret in ADH1 - TipRanks
BridgeBio (NASDAQ: BBIO) files NDA as encaleret hits Phase 3 goals in ADH1 - Stock Titan
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO) - Insider Monkey
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches - Barchart.com
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026Slideshow - Seeking Alpha
BridgeBio Oncology (NASDAQ: BBOT) ramps R&D and deepens Q1 2026 loss - Stock Titan
8 Most Promising Biotech Stocks to Buy Now - Insider Monkey
BridgeBio (BBIO) Positioned for Growth According to JPMorgan Ana - GuruFocus
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $102 to $157 - Moomoo
BridgeBio Submits NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 - HCPLive
BridgeBio submits NDA for encaleret to treat rare genetic disorder By Investing.com - Investing.com Australia
HC Wainwright Issues Optimistic Outlook for BBIO Earnings - MarketBeat
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money - Benzinga
BridgeBio submits NDA for encaleret to treat rare genetic disorder - Investing.com
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 - The Manila Times
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial - Yahoo Finance
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival - BioSpace
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma(BBIO.US) Officer Sells US$5.39 Million in Common Stock - Moomoo
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio Pharma (BBIO) Reports Promising Heart Failure Data Ami - GuruFocus
BridgeBio Pharma CEO Neil Kumar sells $5.39m in company stock - Investing.com Australia
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):